MX2023005841A - Anticuerpos anti-marco y usos de estos. - Google Patents

Anticuerpos anti-marco y usos de estos.

Info

Publication number
MX2023005841A
MX2023005841A MX2023005841A MX2023005841A MX2023005841A MX 2023005841 A MX2023005841 A MX 2023005841A MX 2023005841 A MX2023005841 A MX 2023005841A MX 2023005841 A MX2023005841 A MX 2023005841A MX 2023005841 A MX2023005841 A MX 2023005841A
Authority
MX
Mexico
Prior art keywords
marco
antibodies
marco antibodies
generating
methods
Prior art date
Application number
MX2023005841A
Other languages
English (en)
Spanish (es)
Inventor
Leonard G Presta
Joshua Pollack
Linda Liang
Michel Streuli
Venkataraman Sriram
Sayantan Mitra
Nadine Jahchan
Xi Yang
Vladislava Juric
Linnea Haeggblom
Kara Mojica
Original Assignee
Pionyr Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pionyr Immunotherapeutics Inc filed Critical Pionyr Immunotherapeutics Inc
Publication of MX2023005841A publication Critical patent/MX2023005841A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/003—Arrangements for allocating sub-channels of the transmission path
    • H04L5/0044—Allocation of payload; Allocation of data channels, e.g. PDSCH or PUSCH
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W28/00—Network traffic management; Network resource management
    • H04W28/02—Traffic management, e.g. flow control or congestion control
    • H04W28/08—Load balancing or load distribution
    • H04W28/082—Load balancing or load distribution among bearers or channels
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W74/00—Wireless channel access
    • H04W74/08—Non-scheduled access, e.g. ALOHA
    • H04W74/0833—Random access procedures, e.g. with 4-step access
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023005841A 2020-11-18 2021-11-18 Anticuerpos anti-marco y usos de estos. MX2023005841A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063115272P 2020-11-18 2020-11-18
US202163244662P 2021-09-15 2021-09-15
PCT/US2021/059955 WO2022109178A1 (en) 2020-11-18 2021-11-18 Anti-marco antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2023005841A true MX2023005841A (es) 2023-08-16

Family

ID=81588283

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005841A MX2023005841A (es) 2020-11-18 2021-11-18 Anticuerpos anti-marco y usos de estos.

Country Status (10)

Country Link
US (3) US11572407B2 (cg-RX-API-DMAC7.html)
EP (1) EP4247419A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023549555A (cg-RX-API-DMAC7.html)
KR (1) KR20230121759A (cg-RX-API-DMAC7.html)
AU (1) AU2021382658A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198579A1 (cg-RX-API-DMAC7.html)
IL (1) IL302874A (cg-RX-API-DMAC7.html)
MX (1) MX2023005841A (cg-RX-API-DMAC7.html)
TW (1) TW202237648A (cg-RX-API-DMAC7.html)
WO (1) WO2022109178A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237648A (zh) 2020-11-18 2022-10-01 美商開拓免疫醫療公司 抗marco抗體及其用途
US20250011410A1 (en) * 2021-11-23 2025-01-09 Invetx, Inc. Anti-ngf antibodies and uses thereof
US20260008844A1 (en) * 2022-09-15 2026-01-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Use of anti-marco antibody with a checkpoint blockade antibody for the treatment of cancer
US20260126450A1 (en) * 2022-10-12 2026-05-07 Massachusetts Institute Of Technology Library-scale methods for polypeptide functional analysis
WO2025102054A1 (en) * 2023-11-09 2025-05-15 Massachusetts Institute Of Technology Methods of screening for secreted functional molecules

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916766A (en) 1996-05-23 1999-06-29 Smithkline Beecham Corporation Human marco scavenger receptor
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
US20100227415A1 (en) 2007-07-24 2010-09-09 Iss Immune System Stimulation Ab Method and means for prediction of systemic lupus erythematosus susceptibility
US8597946B2 (en) 2008-03-10 2013-12-03 H. Lee Moffitt Caner Center and Research Institute, Inc. Enhanced dendritic cells for cancer immunotherapy
KR20130108295A (ko) * 2010-08-13 2013-10-02 베일러 리서치 인스티튜트 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
WO2012122396A1 (en) 2011-03-08 2012-09-13 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
WO2016196612A1 (en) 2015-06-01 2016-12-08 The Rockefeller University Anti-tumor agents and methods of use
WO2017062363A1 (en) 2015-10-05 2017-04-13 Joslin Diabetes Center Methods of use of betatrophin
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
EP3612563A1 (en) 2017-04-19 2020-02-26 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
TW201904588A (zh) 2017-06-25 2019-02-01 美商西雅圖免疫公司 引導及導航控制蛋白質之製造及使用方法
EP3668899A4 (en) 2017-08-18 2020-09-02 Celdara Medical, LLC CELL-BASED THERAPIES TARGETING DISEASE-ASSOCIATED MOLECULAR MEDIATORS OF FIBROTIC, INFLAMMATORY AND AUTOIMMUNE DISEASES
PL3688155T3 (pl) 2017-09-28 2023-09-11 Immpact-Bio Ltd. Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar)
MX2020006654A (es) 2017-12-22 2020-11-06 Atossa Therapeutics Inc Métodos intraductales de tratamiento de trastornos de mama.
MX387358B (es) 2018-02-28 2025-03-18 Pfizer Variantes de il-15 y usos de las mismas
BR112021006100A2 (pt) 2018-09-28 2021-07-20 Immpact-Bio Ltd. métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer
JP2022514215A (ja) * 2018-12-05 2022-02-10 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ Rankアンタゴニストおよびその使用
EP3906055A4 (en) 2019-01-04 2023-01-04 Trio Pharmaceuticals, Inc. MULTISPECIFIC PROTEIN MOLECULES AND THEIR USES
WO2020162696A1 (ko) 2019-02-08 2020-08-13 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
US20220152148A1 (en) 2019-03-18 2022-05-19 The Broad Institute, Inc. Modulation of type 2 immunity by targeting clec-2 signaling
IL287801A (en) 2019-05-07 2022-07-01 Immunicom Inc Increasing responses to checkpoint inhibitors by extracorporeal apheresis
GB2603044B (en) 2019-06-11 2024-08-21 Myeloid Therapeutics Inc Macrophage specific engager compositions and methods of use thereof
KR20220054305A (ko) 2019-07-31 2022-05-02 온코어 파마, 인크. 면역 회피성 종양의 치료
TW202237648A (zh) 2020-11-18 2022-10-01 美商開拓免疫醫療公司 抗marco抗體及其用途

Also Published As

Publication number Publication date
CA3198579A1 (en) 2022-05-27
US20260172900A1 (en) 2026-06-18
JP2023549555A (ja) 2023-11-27
WO2022109178A9 (en) 2023-07-13
WO2022109178A1 (en) 2022-05-27
US11572407B2 (en) 2023-02-07
TW202237648A (zh) 2022-10-01
IL302874A (en) 2023-07-01
US12378311B2 (en) 2025-08-05
AU2021382658A1 (en) 2023-07-06
EP4247419A4 (en) 2024-11-06
US20220153832A1 (en) 2022-05-19
EP4247419A1 (en) 2023-09-27
US20240084000A1 (en) 2024-03-14
KR20230121759A (ko) 2023-08-21

Similar Documents

Publication Publication Date Title
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
ZA202309516B (en) Anti-ccr8 antibodies
ZA202204437B (en) Anti-pd-l1 antibodies and antibody-drug conjugates
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12020551710A1 (en) Anti-hla-g antibodies and use thereof
MX2025010681A (es) Formulaciones transdermicas
ZA202206670B (en) Anti-ly6g6d antibodies and methods of use
PH12022550646A1 (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
CR20210088A (es) Composiciones de anticuerpos fcrn y métodos de uso de estos
ZA202307404B (en) Anti-met antibodies and uses thereof
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
PH12020551292A1 (en) Moscato wine replicas produced from individual components
MX2024001243A (es) Composiciones y metodos para el tratamiento de melanoma.
MX2023004280A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea.
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
MX2023011919A (es) Construcciones de proteinas de union a antigenos y anticuerpos y usos de estos.
MX2024014079A (es) Inhibidores de la proteina cinasa activada por mitogeno (mek) y usos de estos
SA521422250B1 (ar) أجسام مضادة للبيريوستين واستخداماتها
PH12021551195A1 (en) Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
ZA202401405B (en) Compositions and methods for anti-pacap antibodies
MX2022015206A (es) Anticuerpos anti-hbv y metodos de uso.
CL2023003151A1 (es) Anticuerpos anti-notch2 y métodos de uso
WO2021164704A3 (en) Enhanced expression system and methods of use thereof